

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			
		Application Number	
		Filing Date	June 25, 2003
		First Named Inventor	Birgit K. Jaitner
		Art Unit	1635
		Examiner Name	
Sheet	1	of	1
		Attorney Docket Number	59516-275 / PP-18707.002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM		HART, T.C., <i>A Mutation in the SOS1 Gene Causes Hereditary Gingival Fibromatosis Type 1</i> , AM. J. HUM. GENET. 70:943-954, 2002	
		NYHUS, J.K., <i>Direct in vivo Transfection of Antisense Fas-ligand Reduces Tumor Growth and Invasion</i> , GENE THERAPY 8:209-214, 2001	
		QIAN, X. et al., <i>The Sos1 and Sos2 Ras-specific Exchange Factors: Differences in Placental Expression and Signaling Properties</i> , THE EMBO JOURNAL 19:642-654, 2000	
		SIBILIA, M. et al., <i>The EGF Receptor Provides an Essential Survival Signal for SOS-Dependent Skin Tumor Development</i> , CELL 102:211-220, 2000	
		BRANCH, A.D., <i>A Good Antisense Molecule is Hard to Find</i> , TIBS 23:45-50, 1998	
		ANAZODO, M.I. ET AL., <i>Relative Levels of Inhibition of p24 Gene Expression by Different 20-mer antisense Oligonucleotide Sequences Targeting Nucleotides +1129 to +1268 of the HIV-1 gag Genome: an Analysis of Mechanism</i> , BIOCHEM. BIOPHYS. RES COMMUN. 229:305-309, 1996	
		HIROTA, Y. et al., <i>p53 Antisense Oligonucleotide Inhibits Growth of Human Colon Tumor and Normal Cell Lines</i> , JPN. J. CANCER RES. 87:735-742, 1996	
		GILES, R.V. et al., <i>Single Base Discrimination for Ribonuclease H-Dependent Antisense Effects Within Intact Human Leukemia Cells</i> , NUCLEIC ACIDS RESEARCH 23:954-961, 1995	
		GISHIZKY, M.L., <i>Tyrosine Kinase Induced Mitogenesis. Breaking the Link with Cancer</i> , IN ANNUAL REPORTS IN MEDICINAL CHEMISTRY 30:247-253 (Academic Press, Inc., 1995)	
		PANDEY, P. et al., <i>Association of the DF3/MUC1 Breast Cancer Antigen with Grb2 and the Sos/Ras Exchange Protein</i> , CAN RES. 55:4000-4003, 1995	
		WITTY, J.P. et al., <i>Modulation of Matrolysin Levels in Colon Carcinoma Cell Lines Affects Tumorigenicity in vivo</i> , CAN. RES. 54:4805-4812, 1994	
		HASELHOFF, J. et al., <i>Simple RNA enzymes with New and Highly Specific Endoribonuclease Activities</i> , NATURE 334:585-591, 1988	
		WALBOT, V. et al., <i>Plant Development and Ribozymes for Pathogens</i> , NATURE 334:196-197, 1988	
		FORSTER, A.C. et al., <i>Self-Cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites</i> , CELL 49:211-220, 1987	
SM		UHLENBECK, O.C., <i>A Small Catalytic Oligoribonucleotide</i> , NATURE 328:596-600, 1987	

Examiner Signature	/Sean McGarry/	Date Considered	04/24/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Arlington, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.



(Use as many sheets as necessary)

Sheet	1
-------	---

1

○

2

Application Number	10/609,150
Filing Date	June 25, 2003
First Named Inventor	Birgit K. Jaitner
Art Unit	4023 1635
Examiner Name	
Attorney Docket Number	59516-275/PP-18707.002

[illegible][illegible]

Examiner Signature	/Sean McGarry/	Date Considered	04/24/2006
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds of Documents of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard SI. 18 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22314-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/609,150		
		Filing Date	June 25, 2003		
		First Named Inventor	Birgit K. Jaitner		
		Art Unit	4623 1635		
		Examiner Name			
Sheet	2	of	2	Attorney Docket Number	59516-275/PP-18707.002

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM		WEINTRAUB ET AL., <i>Antisense RNA and DNA: Molecules That Bind With Specific Messenger RNA's Can Selectively Turn Off Genes. Eventually Certain Diseases May Be Treated With Them; Today Antisense Molecules Are Valuable Research Tools</i> , SCIENTIFIC AMERICAN, 40-45, 1990.	

Examiner Signature	/Sean McGarry/	Date Considered	04/24/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/609,150
Filing Date	06-25-2003
First Named Inventor	Birgit K. Jaitner
Art Unit	4623-1635
Examiner Name	Unassigned
Attorney Docket Number	PP018707.0002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SM	CA	CHIN, Andrew, CD-ROM document, entitled "On the Preparation and Utilization of Isolated and Purified Oligonucleotides," including copy of letter, dated May 12, 2005 from Andrew Chin	

Examiner Signature	/Sean McGarry/	Date Considered	04/24/2006
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.